Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: matsuzawa y. J Clin Med Res. 2016 Feb;8(2):116-25. doi: 10.14740/jocmr2417w. Epub 2015 Dec 28. J Clin Med Res. 2016. PMID: 26767080 Free PMC article.
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: matsuzawa y. J Clin Med Res. 2016 Mar;8(3):267. doi: 10.14740/jocmr2417wc1. Epub 2016 Jan 26. J Clin Med Res. 2016. PMID: 26858805 Free PMC article.
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Kawata T, et al. Among authors: matsuzawa y. J Clin Med Res. 2017 Jul;9(7):586-595. doi: 10.14740/jocmr3038w. Epub 2017 May 22. J Clin Med Res. 2017. PMID: 28611859 Free PMC article.
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study.
Tsurutani Y, Omura M, Matsuzawa Y, Saito J, Higa M, Taniyama M, Nishikawa T; SINGLE-Y investigation group. Tsurutani Y, et al. Among authors: matsuzawa y. Curr Ther Res Clin Exp. 2017 Mar 10;84:26-31. doi: 10.1016/j.curtheres.2016.12.002. eCollection 2017. Curr Ther Res Clin Exp. 2017. PMID: 28761576 Free PMC article.
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
Iemitsu K, Kawata T, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iemitsu K, et al. Among authors: matsuzawa y. J Clin Med Res. 2017 Sep;9(9):793-801. doi: 10.14740/jocmr3116w. Epub 2017 Jul 27. J Clin Med Res. 2017. PMID: 28811858 Free PMC article.
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Tsurutani Y, Nakai K, Inoue K, Azuma K, Mukai S, Maruyama S, Iizuka T, Matsuzawa Y, Saito J, Omura M, Nishikawa T. Tsurutani Y, et al. Among authors: matsuzawa y. Diabetes Obes Metab. 2018 Nov;20(11):2675-2679. doi: 10.1111/dom.13421. Epub 2018 Jul 4. Diabetes Obes Metab. 2018. PMID: 29893003 Clinical Trial.
Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.
Matsuba I, Kanamori A, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Tanaka Y. Matsuba I, et al. Among authors: matsuzawa y. Diabetes Technol Ther. 2020 Mar;22(3):228-234. doi: 10.1089/dia.2019.0372. Epub 2020 Feb 3. Diabetes Technol Ther. 2020. PMID: 32013567 Clinical Trial.
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Matsuba I, et al. Among authors: matsuzawa y. J Diabetes Investig. 2020 Sep;11(5):1248-1257. doi: 10.1111/jdi.13248. Epub 2020 Apr 25. J Diabetes Investig. 2020. PMID: 32149469 Free PMC article.
Survey of the current status of subclinical coronavirus disease 2019 (COVID-19).
Matsuba I, Hatori N, Koido N, Watanabe Y, Ebara F, Matsuzawa Y, Nishikawa T, Kunishima T, Degawa H, Nishikawa M, Ono Y, Kanamori A. Matsuba I, et al. Among authors: matsuzawa y. J Infect Chemother. 2020 Dec;26(12):1294-1300. doi: 10.1016/j.jiac.2020.09.005. Epub 2020 Sep 6. J Infect Chemother. 2020. PMID: 32958395 Free PMC article.
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Matsuba I, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Kanamori A. Matsuba I, et al. Among authors: matsuzawa y. Diabetes Obes Metab. 2021 Dec;23(12):2614-2622. doi: 10.1111/dom.14508. Epub 2021 Aug 12. Diabetes Obes Metab. 2021. PMID: 34338409
1,312 results